FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=919722
Read original at benzingaStocks · News reference
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 9:22 PM
- Checked
- Aug 6, 2026, 9:22 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Read original at benzingaX4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Read original at benzinga